#United States #New York #Pomerantz Law Firm #Sarepta Therapeutics #ELEVIDYS

Pomerantz Law Firm’s Investor Alert

The Pomerantz Law Firm has recently informed investors about a class action lawsuit targeting Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This action arises from concerns that Sarepta, along with some of its executives, might have engaged in illegal business practices or misrepresented facts pertaining to its operations. Investors who suffered losses during this period are strongly encouraged to consider their legal options.

Details of the Class Action Suit

The deadline to be appointed as Lead Plaintiff in this case is quickly approaching, with August 25, 2025, set as the final date. To qualify, investors must have either purchased or acquired Sarepta securities during the specified Class Period. Those interested in joining the class action can access pertinent information by contacting Danielle Peyton at Pomerantz LLP. For convenience, inquiries made via email should include necessary details such as mailing address and phone number, as well as the quantity of shares purchased.

Timeline of Events Leading to the Lawsuit

The class action lawsuit results from a collection of unsettling events related to Sarepta’s drug development. On March 18, 2025, Sarepta made a news announcement regarding the death of a young man suffering from Duchenne muscular dystrophy, which occurred after he received treatment with ELEVIDYS. This tragic incident raised significant concerns about the drug’s safety, prompting a sharp decline in Sarepta’s stock price. In a single day, the company's shares plummeted by 27.44%, closing at $73.54.

Following this, on April 4, 2025, the company disclosed that authorities from a European Union member state requested a meeting with an independent data monitoring committee to review the previously reported death. Concurrently, Sarepta announced it would pause recruitment and dosing for several ELEVIDYS clinical studies. This news contributed to an additional stock price dip, with shares falling by 7.13% to close at $54.43.

On June 15, 2025, another devastating announcement came from Sarepta, revealing a second fatal case of acute liver failure in a patient treated with ELEVIDYS. In response, the company halted its ongoing clinical trials and temporarily suspended the distribution of ELEVIDYS for non-ambulatory patients. Following this revelation, Sarepta’s stock suffered a staggering drop, with a decline of 42.12%, resulting in a closing price of just $20.94 on June 16, 2025.

Furthermore, on June 24, 2025, the U.S. Food and Drug Administration (FDA) issued a Safety Communication highlighting reports of two fatalities connected to the treatment. The FDA's announcement indicated an ongoing evaluation regarding the potential acute liver failure risks associated with ELEVIDYS, referencing the need for further regulatory actions. Consequently, Sarepta's stock price took another hit, falling by 8.01% to close at $17.46.

About Pomerantz LLP

Pomerantz LLP is well-known across the globe and holds a prominent position in corporate and securities class action litigation. Established by Abraham L. Pomerantz, a pioneer in the field, the firm has spent over 85 years dedicated to advocating for victims of securities fraud and corporate misconduct. Their successful track record includes substantial financial recoveries for numerous investors.

For more information about the class action lawsuit or to learn about your rights as an investor, visit Pomerantz Law Firm. It is crucial for affected investors to act swiftly, as time is running out to engage with this significant legal opportunity.